Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1975 of 2051 entries
View as:

Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)

Phase: N/A Priority: Normal
NCT ID: NCT00359671 Org: User:
Start: 12/31/06 End: 07/31/07 Due: 07/31/08

Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00202839 Org: User:
Start: 03/31/05 End: 07/31/08 Due: 07/31/09

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Phase: N/A Priority: Normal
NCT ID: NCT01971554 Org: User:
Start: 10/14/13 End: 04/26/14 Due: 04/26/15

A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)

Phase: N/A Priority: Normal
NCT ID: NCT00254553 Org: User:
Start: 07/31/05 End: 01/31/07 Due: 01/31/08

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase: N/A Priority: Normal
NCT ID: NCT06797635 Org: User:
Start: 03/20/25 End: 12/31/34 Due: 12/31/35

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Phase: N/A Priority: Normal
NCT ID: NCT06136598 Org: User:
Start: 01/30/24 End: 03/14/27 Due: 03/14/28

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00780585 Org: User:
Start: 04/30/07 End: 01/31/09 Due: 01/31/10

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Phase: N/A Priority: Normal
NCT ID: NCT05406401 Org: User:
Start: 07/14/22 End: 04/26/29 Due: 04/26/30

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Phase: N/A Priority: Normal
NCT ID: NCT05953740 Org: User:
Start: 09/15/23 End: 02/15/24 Due: 02/15/25

A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092339 Org: User:
Start: 08/01/02 End: 09/15/02 Due: 09/15/03

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Phase: N/A Priority: Normal
NCT ID: NCT06596668 Org: User:
Start: 10/02/24 End: 03/11/25 Due: 03/11/26

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Phase: N/A Priority: Normal
NCT ID: NCT04003636 Org: User:
Start: 09/24/19 End: 04/01/25 Due: 04/01/26

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)

Phase: N/A Priority: Normal
NCT ID: NCT03830333 Org: User:
Start: 03/20/19 End: 10/14/20 Due: 10/14/21

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Phase: N/A Priority: Normal
NCT ID: NCT04031846 Org: User:
Start: 09/04/19 End: 08/05/21 Due: 08/05/22

Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)

Phase: N/A Priority: Normal
NCT ID: NCT00764660 Org: User:
Start: 02/13/09 End: 07/08/10 Due: 07/08/11

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Phase: N/A Priority: Normal
NCT ID: NCT00529373 Org: User:
Start: 09/13/07 End: 02/01/17 Due: 02/01/18

Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

Phase: N/A Priority: Normal
NCT ID: NCT00132912 Org: User:
Start: 08/30/05 End: 01/28/07 Due: 01/28/08

Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Phase: N/A Priority: Normal
NCT ID: NCT01641666 Org: User:
Start: 05/31/14 End: 09/30/16 Due: 09/30/17

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT01760460 Org: User:
Start: 03/14/13 End: 03/04/15 Due: 03/04/16

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00060632 Org: User:
Start: 04/30/03 End: 10/31/05 Due: 10/31/06

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT01311882 Org: User:
Start: 04/30/11 End: 11/30/11 Due: 11/30/12

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

Phase: N/A Priority: Normal
NCT ID: NCT00687219 Org: User:
Start: 06/30/07 End: 10/31/10 Due: 10/31/11

A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)

Phase: N/A Priority: Normal
NCT ID: NCT00481702 Org: User:
Start: 12/31/01 End: 06/30/03 Due: 06/30/04

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00112372 Org: User:
Start: 05/31/05 End: 03/31/09 Due: 03/31/10

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Phase: N/A Priority: Normal
NCT ID: NCT01544920 Org: User:
Start: 05/30/12 End: 05/19/15 Due: 05/19/16